ABBV vs ADBE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Adobe Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Adobe Inc. · Technology
$248.16
+163.1% upside to fair value
High Conviction
Grade B
QuantHub Verdict
ADBE has more upside to fair value
(+163.1%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ADBE |
| Current Price |
$208.05 |
$248.16 |
| Fair Value Estimate |
$217.50 |
$653.00 |
| Upside to Fair Value |
+4.5%
|
+163.1%
|
| Market Cap |
$367.9B |
$101.2B |
| Forward P/E |
14.9x
|
14.1x
|
| EV / EBITDA |
16.7x
|
—
|
| Price / Sales |
6.1x
|
4.1x
|
| Price / FCF |
20.9x
|
9.8x
|
| Revenue Growth YoY |
+8.6%
|
+3.3%
|
| Gross Margin |
83.7%
|
89.1%
|
| Operating Margin |
34.7%
|
36.6%
|
| Return on Equity |
-129.24%
|
62.3%
|
| Dividend Yield |
3.2% |
— |
| FCF Yield |
4.78%
|
10.2%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Accumulation Zones
| Metric |
ABBV |
ADBE |
| Zone Low |
$163.13 |
$490.00 |
| Zone High |
$184.88 |
$555.00 |
| In Buy Zone? |
No
|
Yes
|